Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO). D'Haens G, et al. Among authors: carbonnel f. Gastroenterology. 2012 Dec;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031. Epub 2012 Sep 20. Gastroenterology. 2012. PMID: 23000597 Review.
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group. Peyrin-Biroulet L, et al. Among authors: carbonnel f. Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25. Gastroenterology. 2011. PMID: 21708105
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.
Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J; European Crohn's and Colitis Organisation (ECCO). Van Assche G, et al. Among authors: carbonnel f. J Crohns Colitis. 2010 Feb;4(1):63-101. doi: 10.1016/j.crohns.2009.09.009. Epub 2009 Dec 21. J Crohns Colitis. 2010. PMID: 21122490 No abstract available.
[Metabolic adaptation to malnutrition].
Carbonnel F. Carbonnel F. Ann Med Interne (Paris). 2000 Dec;151(8):644-51. Ann Med Interne (Paris). 2000. PMID: 11173708 Review. French.
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Fautrel B, Bouhnik Y, Salliot C, Carbonnel F, Fumery M, Bernardeau C, Maugars Y, Flamant M, Coury F, Braithwaite B, Hateb S, Addison J; PERFUSE investigators. Fautrel B, et al. Among authors: carbonnel f. Drugs Real World Outcomes. 2025 Jan 16. doi: 10.1007/s40801-024-00477-4. Online ahead of print. Drugs Real World Outcomes. 2025. PMID: 39821191 No abstract available.
Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis.
Meyer A, Chan SSM, Touvier M, Julia C, Tjønneland A, Kyrø C, Dahm CC, Katzke VA, Schulze MB, Tumino R, Sacerdote C, Masala G, Oldenburg B, Guevara M, Bujanda L, Cabrera Castro NA, Tong TYN, Heath AK, Deschasaux-Tanguy M, Hercberg S, Galan P, Mahamat-Saleh Y, Severi G, Carbonnel F, Amiot A. Meyer A, et al. Among authors: carbonnel f. Aliment Pharmacol Ther. 2025 Jan 16. doi: 10.1111/apt.18497. Online ahead of print. Aliment Pharmacol Ther. 2025. PMID: 39817326
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events.
Shatila M, Zhang HC, Shirwaikar Thomas A, Machado AP, Naz S, Mittal N, Catinis C, Varatharajalu K, Colli Cruz C, Lu E, Wu D, Brahmer JR, Carbonnel F, Hanauer SB, Lashner B, Schneider B, Thompson JA, Obeid M, Farris DP, Wang Y. Shatila M, et al. Among authors: carbonnel f. J Immunother Cancer. 2024 Nov 14;12(11):e009742. doi: 10.1136/jitc-2024-009742. J Immunother Cancer. 2024. PMID: 39542654 Free PMC article.
310 results